Expert: Anti-TL1A monoclonal antibody reducing inflammation

Everyday: Blocks inflammatory protein in autoimmune diseases

Targets: ["TL1A"]

Tulisokibart - UC - Ph3 - Topline (ATLAS-UC) Nov 2026

Anti-TL1A for IBD. Key competitor to AbbVie and Roche TL1A programs. Phase 3 in UC and CD.

{"keyRisks":[{"category":"General","description":"AEs in 76%; well tolerated, SAE 15% (none drug-related)"}],"labelSource":"APOLLO-CD Ph2 data","hasBoxedWarning":false}